Trump-era tariffs benefit undervalued AI stocks, while AbbVie acquires Apogee Therapeutics, and regulatory applications for cemdisiran are reviewed by EMA.
1 report, 1 independent
Updated Jun 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Trump-era tariffs benefit undervalued AI stocks, while AbbVie acquires Apogee Therapeutics, and regulatory applications for cemdisiran are reviewed by EMA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
AbbVie
pharmaceutical company
-
European Medicines Agency
highest regulatory authority on medicines in the European Union